AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, announces plans to launch its microRNA Signature ...

AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer ...

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone ...

An artificial intelligence-aided program accurately predicted 5-year survival for early breast cancer on the basis of a tumor's location. (JCO Clinical Cancer Informatics) Actor D ...

Lung cancer screening with low-dose CT could have saved tens of thousands of lives — if only we'd listened to the data back ...

The institute uses assistance from AI to detect lung cancer in its early stages. It also utilizes an ION Navigational platform to create a minimally invasive procedure for the evaluation of lung ...

University Hospitals plans to compare Qure.ai’s lung cancer algorithm against radiologists’ X-ray interpretations.

Amit Gupta, MD, discussed a new collaboration between University Hospitals Cleveland Medical Center and Qure.ai that aims to ...

University Hospitals Cleveland Medical Center is conducting a clinical trial to investigate the efficacy of an artificial ...

University Hospitals Cleveland Medical Center (UH) has announced a groundbreaking collaboration with global healthcare Artificial Intelligence (AI) innovator Qure.ai to deploy chest X-ray AI, ...

On Wednesday morning, April 2, UH announced its partnership with Qure.AI, a global health tech startup, to use its AI ...